The PeptidesBeat Daily Brief

Two minutes. Five days a week. Everything that shifted overnight in the peptide world — regulatory moves, state-law changes, research drops, market signals — distilled into the morning brief.

What you'll get

• Same-day coverage of FDA, PCAC, and state pharmacy board developments.
• Plain-English summaries of new compound research and trial readouts.
• Industry-side intelligence — pharmacy moves, telehealth pivots, supply-chain dynamics.
• Real-time updates around the July 23–24 PCAC meeting.

What you won't get

• Promotional emails from sponsors (we don't run them).
• Sponsored content masquerading as journalism.
• Daily product pitches — the brief is editorial.
• More than one email per weekday morning.

Coming soon: PeptidesBeat Pro

A paid tier — $19/mo or $179/year — launching after the July PCAC meeting. Includes a weekend analysis brief, the quarterly Industry Index research deck, and full archive access. The free brief will remain free, in perpetuity.